Finally, a bidirectional crosstalk between HER2 and other receptors involved in BC such as Notch or TGF-β signaling, lead to resistance to different anti-HER2 treatments and involve higher aggressivity of HER2+BC disease. The gene discussed is ERBB2; the disease is breast cancer.